Times shown are in EST

7:40 am Online Registration & Virtual Coffee

7:50 am Chair’s Opening Remarks

Identifying the Most Meaningful Neoantigens to Accelerate Successful Clinical Development

8:00 am How to Use AI To Solve Bottlenecks in Neo-Epitope Identification


• Important aspects of neo-epitope identification
• How improvement in data generation & machine learning helps in identifying relevant neo-epitopes

8:30 am A CMO’s Approach to Supporting Personalized Peptide Vaccines


• Outline what PolyPeptide has set-up

• Share our approach to regulatory aspects of personalized peptide vaccines

• Review challenges and how they were overcome

9:00 am Utilizing Novel Computational Techniques to Select Effective & Globally Expressed Neoantigens

  • Julia Kodysh Senior Scientist, Computational Research, Icahn School of Medicine, Mount Sinai


• Exploring how best to identify meaningful mutations that will lead to both a T-cell response and a B-cell response and distinguishing irrelevant mutations
• Computational and experimental techniques to identify neoantigens that are widely expressed and dispersed throughout disseminated tumor legions
• Exploring novel neoantigen sources to drive prediction accuracy

9:30 am NEC OncoImmunity- Session Details to Be Confirmed

10:00 am PeptiCRAd, a Platform for Neoantigen Vaccine Delivery in Cancer


• PeptiCRAD is a platform combining oncolytic adenovirus and peptide vaccination in cancer
• Peptide antigens are non-covalently/electrostatically attached to the virus surface without compromising OV activity and generate potent cytotoxic CD8+ T cell responses to tumors
• PeptiCRAd offers an ideal platform to test novel neoantigens preclinically and in the clinic

10:30 am L7 Informatics- Session Details to Be Confirmed

  • Kevin McMahon Associate Director, Precision Therapeutics Solutions, L7 Informatics

11:00 am Virtual Speed Networking


Reinventing the face-to-face networking in the virtual world. We will pair you up with fellow attendees to break the ice and make new and lasting connections!

Looking to the Dark Side for Next Generation Neoantigen Discovery

11:30 am Dark Matter Antigens: Exploration With Molecular & Cellular Tools


• Solid tumors can display exotic peptides presented by HLA at their cell that are discovered by mass spectrometry and have characteristics of tumor-specific antigens
• Molecular tools can be developed to study their broader expression in cancer cell lines and resected cancer specimens
• Cellular tools reveal the suitability of these dark matter antigens as targets for immunotherapy

12:00 pm A Simplified Approach to Accelerated Neoantigen Development


Streamlined production of neoantigens
• Direct transferability from discovery to production
• Compatibility of green approaches to neoantigen production while
maximizing speed and efficiency

12:30 pm Responses to Inhibitory Tumor Antigens, Inhibigens, Suppress Anti-Tumor Immunity & Promote Tumor Growth


• ATLASTM, Genocea’s T cell antigen discovery platform, uniquely identifies surface-presented antigens of anti-tumor T cell responses and antigens of pro-tumor responses (InhibigensTM).
• Inhibigens may be a novel tumor resistance mechanism that generate deleterious, tolerizing immune responses against cancer and should be avoided from vaccines and immunotherapies.
• Inhibigens are found in most cancer patients and the ratio of Inhibigens to neoantigens appears to predict checkpoint inhibitor (CPI) immunotherapy outcomes

1:00 pm Targeting ERAP1: Altering Neoantigen Presentation With a Small Molecule


• Tumor visibility, defined as the level of tumor-specific antigen expression, is shown to strongly correlate with response to checkpoint inhibition and is a vital aspect determining the immunogenicity within the tumor microenvironment
• Grey Wolf have developed inhibitors of ERAP1, an aminopeptidase in the antigen presentation pathway that determines which antigens are presented on the surface of a cell or tumor
• As opposed to developing a vaccine, Grey Wolf ERAP1 small molecule inhibitors alter the immunopeptidome and thus visibility of the tumor, triggering a differentiated T cell response and causing tumor growth inhibition

1:30 pm Whole Framome Cancer Vaccination


• Every tumor analyzed by Whole Genome Sequencing
• Every tumor deep long RNA sequencing
• Identification of all neoantigens resulting from SVs and subsequent RNA splicing

2:00 pm Lunch & Networking

Using Shared Neoantigens for Development of Off-the-Shelf Immunotherapy

2:30 pm ImmunoID NeXT: A Comprehensive Platform for Immuno- Oncology – Improving Neoantigen Prediction, Evaluating Tumor Dynamics, and Immunogenomics Profiling

  • Christelle Johnson Senior Field Applications Scientist, Cancer Genomics & Immuno-Oncology, Personalis


Accurate assessment of mutational landscape and putative neoantigens
from the analytically-validated exome and transcriptome ImmunoID
NeXT platform
• Improved neoantigen presentation and binding predictions through
a machine learning algorithm, SHERPA, built upon high quality
immunopeptidomics training data from mono-allelic, and multi-allelic
• Comprehensive immunogenomics profiling from a single sample to
guide neoantigen-based therapies and biomarker discovery

3:00 pm Nouscom Genetic Vaccine Encoding Shared Neoantigens to Treat Tumors with MicroSatellite Instability (MSI)


• Large neoantigen payload is ensured by Nouscom genetic vaccination
• GAd/MVA heterologous prime/boost results in induction of CD8 T cells
in preclinical models and cancer patients
• T cells trafficking and expansion in the tumor is the key driver of
treatment efficacy

3:30 pm New Class of Antigen-Specific Cancer Active Immunotherapies Based on an Off-the-Shelf Antigen Presenting Cell Line (PDC*line)


• PDC*line is a new potent and scalable therapeutic cancer vaccines based on a proprietary allogeneic cell line of Plasmacytoid Dendritic Cells
• PDC*line is much more potent to prime and boost antitumor antigen, including neoantigens, specific cytotoxic T-cells than conventional vaccines and improves the response to checkpoint inhibitors
• The technology can be applied for any cancer

4:00 pm Development of Shared Neoantigen Vaccines for Off-the-Shelf Cancer Therapy


• Machine learning prediction of shared neoantigens combined with potent viral vector delivery platforms was applied to the development of a cancer vaccine for the treatment of patients with advanced stage solid tumors
• Clinical and translational data from a Phase 1/2 trial will be presented with learnings applied from “bench to bedside and back to bench” studies to optimize shared neoantigen vaccines

4:30 pm Clinical Activity & Immunogenicity of a Neoantigen Immunotherapy in Non-Small Cell Lung Cancer


• An off-the-shelf, Listeria based-neoantigen immunotherapy (ADXS-503) has been developed using 22 most prevalent tumor associated antigens in NSCLC
• Dose escalation with monotherapy and in combination with pembrolizumab have been conducted
• A dose expansion cohort using ADXS-503 as an add-on-therapy to pembrolizumab at progression, has shown potential to reverse resistance to the checkpoint inhibitor

5:00 pm Afternoon Break

Engineering T Cells to Optimize Personalized Neoantigen Cell Therapy

5:30 pm Identification of Novel pHLA Targets for Solid Tumor Targeting With Cancer Vaccines


• Advantages of intracellular targets (pHLAs) versus viral, neoantigens or conventional cell surface antigens
• Strategies to find the most prevalent and immunogenic pHLA targets in tumors from CPI responders
• Selection of self-antigen targets with highest tumor vs normal ratios to avoid off-tumor, on-target toxicities

6:00 pm Unleashing the Titans: The Gen-011 Neoantigen-Targeted Peripheral T Cell Therapy for Solid Tumors


• Adoptive T cell therapies have resulted in unprecedented efficacy against solid tumors
• Prioritizing neoantigens with the ATLASTM bioassay identifies the right targets and avoids pro-tumor InhibigensTM
• The GEN-011 neoantigen-targeted peripheral T cells (NPTs) have broad specificity and are non-exhausted, polyfunctional, cytolytic cells
• The TITAN-1 clinical trial is ongoing (NCT04596033)

6:30 pm Chairman’s Closing Remarks & Close of Day 1